{"id": "chatcmpl-8JZz4NRWMle6cwPgrbtu7ewh63lLs", "object": "chat.completion", "created": 1699677246, "model": "gpt-4-0613", "choices": [{"index": 0, "message": {"role": "assistant", "content": "1. The current study is an open-label randomized phase II study.\n2. The study is testing whether low dose cyclophosphamide can improve antigen-specific immune responses.\n3. The study is also testing whether low dose cyclophosphamide can improve the clinical efficacy of personalized peptide vaccination.\n4. The study involves 49 patients.\n5. The patients involved in the study have been previously treated for aBTC.\n6. The study involves the use of personalized peptide vaccination (PPV).\n7. The study involves the use of low dose cyclophosphamide (CPA)."}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 84, "completion_tokens": 119, "total_tokens": 203}, "temperature": 0, "max_tokens": 512, "top_p": 1, "frequency_penalty": 0, "presence_penalty": 0, "messages": [{"role": "system", "content": "Statement: In the current study, we conducted an open\u2010label randomized phase II study to test whether low dose cyclophosphamide (CPA) could improve antigen\u2010specific immune responses and clinical efficacy of personalized peptide vaccination (PPV) in 49 previously treated aBTC patients.\n\nList all the facts we explicitly know from the statement. Make each fact as atomic as possible."}]}